Drugs / GHZ339
last change May 2025 re-read 3 minutes ago

GHZ339

Developed for
atopic eczema
Investigated by
Novartis Pharmaceuticals

Trials 1

2026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06947993 May 2025 → Nov 2028 expected atopic eczema Novartis Pharmaceuticals Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GHZ339 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06947993 ↗